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Abstract 
 
Objective: The aetiology of Crohn’s disease (CD) has been related to NOD2 and 
ATG16L1 gene variants that disrupt an autophagy-dependent antibacterial pathway. 
The observation of bacterial-DNA translocation in the blood of CD patients led us to 
hypothesize that an impaired immune response may facilitate this process in patients 
with NOD2/ATG16L1-variant genotypes and affect the efficacy of anti-TNF therapies. 
 
Design: 179 patients with Crohn’s disease were included. CD-related NOD2 and 
ATG16L1 variants were genotyped. Phagocytic and bactericidal activities were 
evaluated in blood neutrophils. Bacterial-DNA, TNF-α, IFN-γ, IL-12p40, free serum 
infliximab/adalimumab levels and anti-drug antibodies were measured.  
 
Results: Bacterial-DNA was found in 44% of active patients vs. 23% of patients in 
remission (p=0.01). A NOD2 or ATG16L1-variant genotype was significantly 
associated with the presence of bacterial-DNA (Odds ratio (OR) 4.8; 95%CI 1.1-
13.2; p=0.001, and OR 2.4; 95%CI 1.4-4.7; p=0.01, respectively). This OR was 
12.6 (95%CI 4.2-37.8; p=0.001) for patients with a double-variant genotype. 
Presence of bacterial-DNA in blood was independently associated with disease activity 
(OR 2.6; 95%CI 1.3-5.4; p=0.005). Single and double-gene variants were not 
directly associated with disease activity (p=0.19). Patients bearing a NOD2-variant 
genotype showed significantly decreased phagocytic and bactericidal activities in 
blood neutrophils, increased TNF-α levels in response to bacterial-DNA and 
significantly decreased trough levels of free anti-TNF-α. Interestingly, the proportion 
of patients on an intensified biological therapy was significantly higher in the NOD2-
variant groups.  
 
Conclusion: The results point to the identification of a patient subgroup that might 
require more aggressive therapies to reduce inflammation, the risk of bacterial-DNA 
translocation and relapse. 
 
Electronic word count: 253 
Summary box 
 
What is already known about this subject? 
 
- Genetic susceptibility and the immunological interaction between the host and 
commensal flora are implicated in the aetiology of Crohn’s disease. 
  
- Gut bacterial DNA translocation into blood is a frequent event in patients with 
Crohn’s disease. 
 
- Relapse occurs during the course of the disease in patients with Crohn’s 
disease, even on immunosuppressive and/or biological maintenance 
treatments.  
 
- The efficacy of different therapeutic schemes using biologics to treat patients 
with Crohn’s disease is under discussion.  
 
 
What are the new findings? 
 
- NOD2 and ATG16L1 genetic variants are independent risk factors for bacterial 
DNA translocation in Crohn’s disease. 
 
- Bacterial DNA translocation is directly associated with disease activity and 
increases the risk of relapse at 6 months. 
 
- Patients with a NOD2 variant genotype showed significantly decreased 
phagocytic and bactericidal activities, increased serum TNF-alpha levels in 
response to bacterial-DNA and significantly decreased levels of free serum 
anti-TNF-α. 
 
- In vitro E. coli DNA-stimulated neutrophils from patients with a NOD2 variant 
genotype show lower serum levels of anti-TNF-alpha, suggesting faster drug 
consumption 
 
 
How might it impact clinical practice in the foreseeable future? 
 
- Our results identify a subgroup of patients with an increased risk of bacterial 
DNA translocation and, very likely, an increased risk of relapse. 
 
- Classical anti-TNF-alpha therapy regimens are likely to decrease their efficacy 
in controlling the risk of flare-up in these patients who might require more 
aggressive therapeutic programs to reduce inflammation and episodes of 
bacterial DNA translocation. 
 
 
 
  
 
Introduction 
The understanding of the pathogenesis of Crohn’s disease (CD), one of two major 
forms of inflammatory bowel disease affecting the population worldwide (1;2), has 
experienced enormous progress in recent years. Its aetiology is partially explained by 
a disturbance of the interaction between the host and intestinal microorganisms (3-
6). Accordingly, the gut epithelial barrier plays a crucial role in regulating the uptake 
of luminal antigens and in controlling intestinal immune responses to luminal 
bacteria. Recently, we have reported evidence of bacterial DNA (bactDNA) 
translocation into the blood of CD patients. The associated innate immune response, 
which is partially affected by nucleotide-binding oligomerization domain containing 2 
(NOD2) gene status (7;8), suggests either a dysfunction in the epithelial cell layer, 
an intestinal bacterial overgrowth or the combination of both of these adverse 
events.    
 
NOD2 encodes an intracellular receptor for the presence of muramyl dipeptide (MDP), 
a common component of the bacterial cell wall (9-11) and has been identified as  a 
prominent CD susceptibility gene (12). However, genome-wide association studies 
have increased the number of genes that may potentially modulate CD up to 71 loci 
(13) (14). Among them, the autophagy gene ATG16L1, is very prominent (15-17). 
ATG16L1 is implicated in the modulation of autophagy, an important cell survival 
mechanism also involved in key aspects of the innate immune response to 
microorganisms (18). The CD-associated ATG16L1 variant, T300A, has been reported 
to result in an autophagy defect (15;19), suggesting a role for autophagy, and 
ATG16L1 in particular, in the pathogenesis of CD. 
 
Recently, ATG16L1 and NOD2 have been reported to interact in an autophagy-
dependent antibacterial pathway in response to MDP that is disrupted by specific CD-
associated mutations (20). We have observed that CD patients with a mutated NOD2 
genotype cannot properly respond to bactDNA translocation (8). On the other hand, 
increasing evidence has been reported linking phagocytosis, a primary mechanism of 
host defence against bacterial products, with the autophagy machinery (21;22). 
Therefore, we hypothesize that the presence of bactDNA in the blood of CD patients 
may be associated with functional impairment by the autophagy-related CD-
associated gene mutation, further complicating the disease outcome. 
 
The aim of the present study was to determine whether the presence of NOD2 and 
ATG16L1 mutations confer susceptibility to an impaired phagocytic activity and 
increased rates of bactDNA translocation into the blood of CD patients.  
Patients and methods 
Patients. 
One hundred-seventy-nine consecutive patients diagnosed with CD and controlled in 
the IBD Unit of the Hospital General Universitario de Alicante who accepted to 
participate in the study were included. The diagnosis of CD was established according 
to standard clinical, endoscopic, histological and radiographic criteria (23). Patients 
who had received antibiotics in the previous 2 weeks were not considered for 
inclusion. All patients were classified according to the Montreal classification (24) and 
stratified according to the Crohn’s Disease Activity Index (CDAI). All included patients 
received diaries to record symptoms one week prior to inclusion and sample 
collection. Intensified therapy with biologics was defined either by an increased dose 
or an increase in the frequency of infusions versus dosing or schedule upon start of 
treatment. Twenty-five healthy controls were also included in the study. All patients 
and controls were Caucasian of Mediterranean ethnicity. Blood samples from patients 
and healthy donors were obtained for routine haematological and biochemical studies 
and inoculated in aerobic and anaerobic blood culture bottles, 10mL each. 
Simultaneously, two separate blood samples were inoculated under aseptic conditions 
in rubber-sealed sterile Vacutainer SST II and K3E tubes, respectively (BD 
Diagnostics, Belgium) that were never exposed to free air.  
 
Patients were followed-up for 6 months to evaluate the incidence of relapse. Although 
“relapse” strictly refers to the clinical situation coming from remission, we wanted to 
evaluate whether patients would turn into an active disease form in the next 6 
months after bactDNA detection, no matter their CDAI status at admission. In the 
case of patients with a CDAI>150 at admission, the flare was controlled in all cases 
within the subsequent two weeks.  The Ethics Committee of the hospital approved the 
study protocol. All controls and patients gave informed consent prior to inclusion in 
the study. 
 
Identification of bactDNA fragments and genotyping of CD-associated genes.  
Genomic DNA was isolated from 5x106 cells with the QIAmp DNA Blood Minikit 
(Qiagen, Hilden, Germany). BactDNA was identified by running broad-range PCR 
followed by partial nucleotide sequencing of a conserved region of 16SrRNA gene, as 
previously described (25). The three common NOD2/CARD15 allelic variants at SNP-8 
(R702W, rs2066844), SNP-12 (G908R, rs2066845) and SNP-13 (L1007finsC, 
rs2066847) were evaluated as previously described (26). The ATG16L1 variation 
rs2241880 (T300A) was genotyped by TaqMan technology (Applied Biosystems) 
using commercially available TaqMan SNP Genotyping Assays and TaqMan 
Genotyping Master Mix on a 7900HT Fast Real-Time PCR System using SDS 2.2 
Software (Applied Biosystems). A variant NOD2 genotype (varNOD2) was defined as 
carrying any of the three variants studied either in homozygosis or heterozygosis. A 
variant ATG16L1 genotype (varATG16L1) was defined as carrying the rs2241880 
variation either in homozygosis or heterozygosis. All genotyping results were 
assessed twice. The evaluators were not aware of either the patient’s disease-status 
or each other’s genotype results. A Hardy-Weinberg test was performed as a quality 
control measure in controls. No missing genotypes were present. 
 
Phagocytic and bactericidal assays 
The phagocytic activity of neutrophils that ingest fluorescein-isothiocyanate (FITC)-
labelled opsonized E. coli and the bactericidal activity of neutrophils that oxidize the 
fluorogenic substrate dihydrorhodamine DHR123 to rhodamine R123 (ability to 
generate reactive oxygen species) were determined using the Phagotest and 
Bursttest Kits (Orpegen Pharma, Heidelberg, Germany) following the manufacturer’s 
instructions. Cells were quantified by flow cytometry using a FacsCanto (Becton 
Dickinson, Heidelberg, Germany) and the data were processed using the FacsDiva 
12.0 software (Becton Dickinson). 
 
Serum cytokine and free anti-TNF-α levels. Presence of anti-drug antibodies. 
Enzyme-linked immunosorbent assays (ELISAs) were carried out to measure TNF-α, 
IFN-γ, IL-12p40 (R&D Systems, Minneapolis, MN), free infliximab and adalimumab 
levels and to detect anti-drug antibodies (Matriks Biotek, Ankara, Turkey) according 
to the manufacturers’ instructions. All samples were tested in triplicate and read in a 
Sunrise Microplate Reader (Tecan, Männedorf, Switzerland). The detection limit for 
each cytokine assay varied between 2–5 pg/mL and between 10-30ng/mL in the case 
of free anti-TNF-α kits. The presence of anti-drug antibodies was evaluated by a cut-
off value estimated by multiplying the optical density (OD) of the zero standard by 3, 
as indicated by the manufacturers. Samples were considered positive when the ratio 
sample OD/zero standard OD was higher than 3.   
 
Isolation and culture of human PMN cells. 
To study in vitro the relationship between free anti-TNF-α levels in neutrophils from 
patients with different NOD2/ATG16L1-combined genotypes, PMNs from peripheral 
blood samples were isolated with PolymorphPrepTM (Axis-Shield PoC, Oslo, Norway). 
After isolation of PMNs, cells were washed twice with freshly made PBS at 4ºC. Cell 
viability was evaluated by trypan blue (Sigma, Madrid, Spain). Cells were 
resuspended in phenol red-free RPMI 1640 medium (Gibco BRL, Life Technologies, 
Paisley, UK) supplemented with 10% human serum AB (BioWhittaker, Walkersville, 
MD). Neutrophils (1x106 cells/well) were incubated with 200 ng of E. coli-DNA. Half of 
the supernatant volumes were collected at 24 hours and TNF-α and annexin V levels 
measured by ELISA. Cells were then treated with Infliximab 100ug/mL/106 cells 
(Infliximab was kindly provided by Merck Sharp and Dohme of Spain MSD, Madrid, 
Spain). Supernatants were collected at 48 hours to determine free TNF-α, anti-TNF-α 
and annexin V levels. Total endogenous annexin V levels were evaluated as an 
indirect measurement of apoptotic activity in neutrophils using a human Annexin V 
ELISA kit from Promokine (Heidelberg, Germany), according to manufacturer’s 
instructions. 
 
Statistical Analysis 
Continuous variables are reported as the mean ± standard deviation and categorical 
variables as frequency or percentages. The Kolmogorov-Smirnov test was used to 
test the normality of the distribution of continuous variables. Statistical differences 
were analysed using the chi-squared test for categorical data followed by the post-
hoc Bonferroni correction for multiple comparisons. Quantitative data showing normal 
distribution were analysed using the ANOVA test followed by the post-hoc Bonferroni 
correction for multiple comparisons. Quantitative data showing non-normal 
distribution were analysed using the Mann-Whitney U test or Kruskal-Wallis test 
followed by pairwise comparisons using the Mann-Whitney U test with the post-hoc 
Bonferroni correction for multiple comparisons. Bivariate correlations were analysed 
using the Spearman test. Logistic regression analysis was used to determine the 
association between NOD2/ATG16L1 genotypes and bactDNA concentration or CDAI. 
We first examined clinical and experimental variables by univariate analysis, and then 
by multivariate analysis including significant factors at P<0.10 in univariate analysis. 
Results of logistic regression are reported as odds ratio (OR) and 95% confidence 
interval (95%CI). All reported p-values are two-sided, and p-values less than 0.05 
were considered to indicate significance. All analyses were performed using IBM SPSS 
Statistics 19. 
Results 
Patient characteristics 
The clinical and analytical characteristics of patients included in the study are detailed 
in Table 1, stratified according to the Crohn’s Disease Activity Index (CDAI). No 
statistically significant differences were observed between groups regarding age, 
gender, smoking habit or disease classification by Montreal criteria. Active patients 
showed higher ESR, CRP and lower haemoglobin and albumin levels than patients in 
remission. Steroid treatment was significantly more frequent in active patients. 
Among healthy controls, mean age was 32±11 years, male/female ratio was 12:8, 
and 35% of them were smokers. No differences in demographic and analytical 
parameters between controls and patients in remission were observed. All patients 
and controls included in the study had negative blood microbiological cultures.  
 
NOD2 / ATG16L1 genotypes and serum bactDNA distribution in CD patients. 
The distribution of genotypes and allelic frequencies in CD patients and controls are 
shown in Table 2. All variants were found to be in the Hardy-Weinberg equilibrium in 
the controls. Overall, 69% of patients in remission and 76.4% of active patients 
showed at least one of the CD-associated gene variants. A NOD2 variant, either alone 
or combined with the ATG16L1 variant, was present in 56 (41.2%) patients in 
remission and in 18 (41.8%) active patients. The ATG16L1 variant, either alone or 
combined with a NOD2 variant, was present in 82 (60.2%) patients in remission and 
in 24 (55.8%) active patients. Figure 1A shows the distribution of NOD2 and 
ATG16L1 variants among active CD patients and those in remission. The distribution 
of the genotypes under study was not statistically significant between both groups 
(p=0.90). 
 
From the overall series of patients, 51 out of 179 (28.5%) showed the presence of 
bactDNA in blood samples. By groups, 19 out of 43 clinically active patients (44.2%) 
and 32 out of 136 patients in remission (23.5%) showed bactDNA (p=0.01). The 
identified bacterial species included: Escherichia coli (n=21), Staphylococcus aureus 
(n=12), Klebsiella pneumoniae (n=7), Streptococcus pneumoniae (n=5), Shigella 
spp. (n=3), Enterococcus faecalis (n=2) and Campylobacter freundii (n=1). No 
statistical differences in bacterial species were observed between the studied 
genotypes. As expected, bactDNA was absent in the blood of healthy controls. A 
univariate analysis revealed that the presence of bactDNA in the blood, among 
others, was significantly associated with disease activity with an odds ratio (OR) 2.6 
(95% confidence interval (95%CI) 1.3-5.4; p=0.005) whereas single and double-
gene mutations were not directly associated with disease activity (p=0.19). As 
expected, the use of steroids and infliximab were also significantly associated with 
disease activity, as they are a usual therapeutic first approach on a flare-up 
(Supplementary Table 1). A multivariate analysis including variables showing a p 
value<0.1 on the univariate analysis is detailed in Table 3A. Of note, bactDNA 
remained significantly and independently related to disease activity. 
 
BactDNA was present in 5/47 (10.6%) wtNOD2/wtATG16L1 patients, 8/26 (30.7%) 
varNOD2/wtATG16L1 patients, 9/57 (15.5%) wtNOD2/varATG16L1 patients and 
29/48 (60.4%) varNOD2/varATG16L1 patients. Figure 1B displays the percentage of 
bactDNA presence in each studied genotype, distributed by CDAI. The percentage of 
patients with bactDNA was significantly increased in the varNOD2 genotype groups. 
Unlike the double wild-type genotype, single NOD2 or ATG16L1 variants were 
significantly associated with the presence of bacterial DNA on the univariate analysis 
(OR 4.8; 95%CI 1.1-13.3; p=0.03, and OR 2.4; 95%CI 1.46-4.5; p=0.05, 
respectively). This effect was more pronounced in patients with a double variant 
genotype (OR 12.7; 95%CI 4.2-37.8; p=0.001) (Supplementary Table 2). All studied 
gene variants, as well as disease activity, remained significantly and independently 
associated with the presence of bactDNA on the multivariate analysis (Table 3B). 
 
No differences among the three examined NOD2 allelic variants were observed for 
CDAI or any other clinical characteristics of varNOD2 patients. No statistically 
significant differences were observed, either, between patients stratified by genotype 
or by presence of bactDNA, although CRP, total WBC and CDAI were higher in 
patients with bactDNA (data not shown).  
 
Forty-three patients relapsed during this period (24%): twenty out of 51 patients 
with bactDNA at inclusion (40%) vs. 23 out of 128 patients without bactDNA (18%) 
(p=0.01). BactDNA in the blood, among others, was significantly associated with an 
increased risk of flare-up at 6 months on the initial univariate analysis, with an OR 
3.32 (95%CI 1.5-7.3; p=0.003) (Supplementary Table 3). The multivariate analysis 
revealed bactDNA presence as the only independent factor associated with relapse at 
6 months (Table 3B). Thirty-three patients (18.4%) received short-term courses of 
oral antibiotics during the 6-month follow-up period due to non CD-related causes 
with no statistically significant effect on the risk for relapse among patients, either 
stratified by genotype or by the presence of bactDNA at admission. There was no 
statistical association either between bactDNA presence at admission and the 
subsequent need for antibiotics, complications such as surgery or re-admissions 
during the follow-up period among the different genotype subgroups.  
 
Immunological activity in response to bactDNA in patients with different 
NOD2/ATG16L1 genotypes. 
We evaluated the pro-inflammatory cytokine response to the presence of bactDNA in 
the serum of CD patients, stratified by genotype. The results are shown in Table 4. 
No differences were observed between patient groups without bactDNA. The pro-
inflammatory activity was significantly increased in patients with bactDNA as 
compared with that observed in patients without bactDNA, irrespective of genotype. 
However, patients with bactDNA and a variant NOD2 genotype, either alone or 
combined with a variant ATG16L1 genotype, showed a further statistically significant 
increase as compared with wild-type NOD2 genotype subgroups. Furthermore, the 
highest pro-inflammatory levels were obtained in serum from patients carrying a 
combined NOD2/ATG16L1 double-variant genotype. An ANOVA analysis of pro-
inflammatory cytokines including different variables and their combinations revealed 
that bactDNA and the interaction between bactDNA and genotype were the only 
statistically significant variables (data not shown). 
  
Phagocytic and bactericidal activities were evaluated in blood neutrophils treated with 
a fluorochrome-labelled E. coli from the first 12 patients in remission without 
bactDNA of each genotype-stratified subgroup (n=48). As shown in Figure 2, 
phagocytic and bactericidal activities were significantly decreased in the neutrophils 
of patients with varNOD2/wtATG16L1 and varNOD2/varATG16L1 genotypes, with no 
differences between these two groups. To investigate whether these results were 
affected by ongoing treatment, phagocytic and bactericidal activities were also 
evaluated in healthy controls without bactDNA carrying NOD2 (n=3) and ATG16L1 
(n=5) variants or wild-type (n=10). As in patients, these activities were decreased in 
healthy donors carrying any NOD2 variant as compared with ATG16L1 variant and 
wild-type genotypes (data not shown).   
 
Intensified anti-TNF-α therapy is more frequent in patients with mutated 
NOD2/ATG16L1-combined genotypes. 
Next, we evaluated whether these combined genotypes had an impact on anti-TNF-α 
therapy schedules. Fifty-two (29%) out of the 179 patients were on anti-TNF-α 
therapy at inclusion, either combined with immunosuppressive treatment or not, 30 
on infliximab and 22 on adalimumab (see Table 1). Figures 3A and 3B show the 
percentage of patients on anti-TNF-α therapy and, of those, the percentage of 
patients on an intensified schedule of anti-TNF-α therapy, either stratified by 
genotype or by the presence of bactDNA. As detailed, the proportion of patients on 
intensified therapy was higher in the groups with either a varNOD2/wtATG16L1 or a 
varNOD2/varATG16L1 genotype. No statistically significant differences were observed 
in the percentage of smokers, the time from diagnosis or the time from initiation of 
anti-TNF-α therapy between intensified and non-intensified patients, all of which 
could affect the need for intensification (Supplementary Table 4). Twenty percent of 
patients receiving anti-TNF-α therapy showed bactDNA in blood, of which 50% were 
on an intensified drug schedule. By contrast, only 33% of patients without bactDNA 
received intensified treatment (p=ns). No differences were observed for the 
distribution of each anti-TNF-α among patients, either grouped by genotype or by the 
presence of bactDNA. 
 
Free anti-TNF-α levels were measured in the serum of patients receiving therapy with 
biologics and stratified according to their genotype and the presence of bactDNA. 
Results were restricted to samples that were negative for the presence of anti-drug 
antibodies (n=48) and are shown in Figure 3C. Significantly decreased levels of free 
anti-TNF-α were observed in the varNOD2/wtATG16L1 and varNOD2/varATG16L1 
genotype-based subgroups, despite showing a significant number of patients on an 
intensified schedule. The presence of bactDNA further decreased the levels of free 
serum anti-TNF-α, although the number of individuals was too small to report 
statistics. Since interactions between biologics and azathioprine or methotrexate 
have been described, we repeated the analysis excluding patients on combined 
therapies in samples with an absence of serum anti-drug antibodies (n=24) obtaining 
comparable results (Figure 3D).  
As stated above, three patients out 30 with Infliximab (10%) and 1 patient out of 22 
with Adalimumab (4.5%) showed the presence of anti-drug antibodies (see methods) 
and were excluded from the analyses presented in Figures 3C and 3D. None of these 
patients showed the presence of bactDNA in blood. Two of them had a 
wtNOD2/wtATG16L1 genotype and were on combined therapy. One patient had a 
wtNOD2/wtATG16L1 genotype and was on monotherapy with Infliximab. One patient 
had a wtNOD2/varATG16L1 genotype and was on monotherapy with Adalimumab. 
 
Free anti-TNF-α levels are decreased in the supernatants of neutrophils from variant 
NOD2/ATG16L1 patients exposed to bactDNA.  
We designed an in vitro experiment with neutrophils isolated immediately before 
anti-TNF-alpha infusion (trough levels) from the same 12-patient genotype-stratified 
subgroups without bactDNA, excluding those that showed the presence of anti-drug 
antibodies. Results are shown in Figure 4. 
 
Levels of TNF-α were significantly increased after 24-hour E. coli bactDNA stimulation 
in the subgroups bearing a variant vs. wild-type NOD2 genotype (Figure 4A). 
Baseline and 24-hour unstimulated supernatant levels are also represented. No 
differences in the apoptotic activity of neutrophils at this time-point were observed 
among groups (Figure 4B). Forty-eight hours after anti-TNF-α addition, levels of TNF-
α were significantly decreased in all subgroups with wild-type NOD2. This reduction 
was not observed in the supernatants of cells with a NOD2 variant. On the other 
hand, a significant reduction in free anti-TNF-α levels was found in the supernatants 
of the subgroups carrying a variant NOD2 genotype, either alone or combined, 
compared with wild-type NOD2 (Figure 4C). No differences in apoptotic activity of 
neutrophils between groups were observed at this time-point either (Figure 4D). 
 
Discussion 
Patients bearing a NOD2 variant genotype, either alone or combined with an 
ATG16L1 variant genotype, show an increase in secreted TNF-alpha levels in 
response to bactDNA translocation and, therefore, a faster consumption of free anti-
TNF-alpha. From a clinical perspective, this may lead to a significantly higher 
percentage of patients requiring an intensified anti-TNF-alpha therapy among variant 
NOD2/ATG16L1 genotypes as compared to wild-type. This may contribute to the 
identification of a subgroup of patients that not only require more aggressive 
therapies to control inflammation but also have an increased risk of bactDNA 
translocation and, most likely, an increased risk of relapse.    
 
The present study further indicates that the grade of disease activity in CD patients is 
associated with an increased rate of bactDNA translocation, which in turn is 
significantly associated with a single or, especially, with a combined NOD2/ATG16L1-
variant genotype. The increased pro-inflammatory response observed in patients with 
translocated bactDNA is further complicated by the impaired phagocytic and 
bactericidal activities of neutrophils from patients carrying NOD2 gene variants. This 
seems to further affect the efficacy of anti-TNF-alpha therapies. These results are in 
keeping with several previous reports linking NOD2 variants with higher risk of 
complicated CD (27-29) 
 
The number of IBD-associated susceptibility genes has increased in recent years to 
over 100 at present (16;30). Among them, autophagy-related genes, especially 
ATG16L1, have emerged as new key players (15;17) along with others that were 
previously identified, such as NOD2, classically associated with the development of 
CD (26). However, none of them has been linked so far with the risk of disease flare-
ups.  Although the association between these gene variants and disease activity was 
not found in our study, they were significantly associated, either alone or combined, 
with the presence of bactDNA in blood of CD patients and this fact was in turn 
significantly associated with disease activity. These results suggest that bactDNA 
translocation might be facilitated in patients with variant NOD2/ATG16L1-combined 
genotypes increasing the risk of flare in these patients, as shown in Figure 1. In fact, 
genetic interactions between polymorphisms in toll-like receptor (TLR)-9, the specific 
receptor for immunogenic CpG motifs present in bactDNA and CD-associated variants 
in NOD2 and other genes, have been previously described (31).  
 In our study, patients bearing a NOD2 gene variant, either alone or combined with a 
variant ATG16L1 genotype, showed significantly reduced phagocytic and bactericidal 
activity (Figure 2). NOD2 genetic alterations have also been associated with a 
defective innate response in the past (32). Interestingly, our data indicates that 
NOD2 may be involved in the phagocytic and bactericidal capacities of blood 
neutrophils, facilitating its ability to clear bacteria and their components from the 
blood of these patients. We hypothesized that the persistence of bactDNA fragments 
in the blood of NOD2-mutated patients would correlate with an increased pro-
inflammatory cytokine response. Accordingly, in addition to the increased pro-
inflammatory response to bactDNA presence in wild-type patients, which is in line 
with previous results in this and other settings (8;33), data shown in Table 4 
revealed that NOD2 mutated genotypes were associated with further increments in 
the concentration of these cytokines. 
 
The established efficacy of anti-TNF-α therapies in CD (34-37) has supported the role 
of TNF-α as a key player in CD immunopathogenesis. Our results led us to investigate 
the potential clinical effect of different NOD2/ATG16L1 genotypes and bactDNA 
presence on the inflammatory response in CD patients receiving treatment with 
biologics. The proportion of patients on intensified treatment was significantly higher 
in patients with a variant NOD2/ATG16L1-combined genotype. At the same time, free 
anti-TNF-α levels were significantly decreased in the serum of patients bearing any of 
the NOD2 variants and especially in those with a combined NOD2/ATG16L1 variant 
genotype. As the presence of anti-drug antibodies is a well-known factor affecting 
drug levels, the analyses were performed considering only patients without serum 
anti-drug antibodies. These data are clinically relevant since free anti-TNF-α levels 
represent the available drug in the blood of patients. Low serum anti-TNF-α levels 
have been associated with a lack or loss of response and therapeutic drug monitoring 
has been suggested as a useful tool in the clinical management of CD patients (38-
40). Inter-individual variability has been a constant flaw in studies reporting 
pharmacokinetic data on anti-TNF-α levels so far. The use of concomitant drugs such 
as azathioprine or methotrexate has also been reported to influence clearance of 
anti-TNF-α and the development of immunogenicity (41;42). We also analysed the 
subgroup of patients exclusively on anti-TNF-α monotherapy. In our series, results 
were similar although variability was reduced in patients on monotherapy. These 
results suggest that not only combined therapies but also NOD2/ATG16L1 genotypes 
and the presence of bactDNA may account for the high variability observed in serum 
free anti-TNF-α levels and might provide an explanation for the need for intensified 
anti-TNF-α therapy. One may think of the intensified biological schedule as the cause 
for the increased bacterial translocation and the subsequent bactDNA detection in the 
varNOD2 group. However, only 20% of patients on anti-TNF-α therapy have bactDNA 
and, of those, 50% were intensified. This percentage was not significantly different 
from the 33% of patients without bactDNA who were on drug intensification. Besides, 
if that were the case, lower bactDNA rates might be expected in varNOD2 patients 
without vs. with biological therapy but bactDNA is present in 52.7% of varNOD2 
patients without vs. 29.4% of varNOD2 patients with anti-TNF-α therapy (p=ns).  
 
To further support our assumption, we designed an in vitro experiment on 
neutrophils obtained from patients without bactDNA carrying different genotypes at 
the time of anti-TNF-α drug infusion (trough level). After bactDNA stimulation and 
addition of a known Infliximab dose, free drug levels were significantly lower in 72-
hour supernatants of cells from patients bearing a double-mutated genotype, 
suggesting an accelerated drug consumption rate in these patients. Although the 
highest TNF-α levels were observed in samples from mutated genotypes treated with 
E. coli DNA and despite the fact that 24-hour unstimulated cells didn’t show an 
increase in TNF-α compared to baseline, the possibility of an inflammatory peak, 
earlier to or independent of BT, is not completely ruled out. Nevertheless, these 
results point to the identification of a subgroup of CD patients with the potential need 
for a more aggressive therapeutic approach to efficiently control their disease course 
or, at least, in which the current therapies are not as effective as in patients with a 
wild-type NOD2 genotype. In fact, studies have already been conducted to evaluate 
“top-down” vs. “step-up” therapies and these strategies are presently under 
discussion (43;44). Besides, the presence of bactDNA was significantly associated in 
our series with relapse in the 6-month follow-up period. Although evaluating risks 
factors for relapse was not the aim of this study, the preliminary data reported here 
supports the design and development of new specifically designed studies including 
multivariate analysis of known risk factors for the clinical course of the disease such 
as the lack of mucosal healing (45), the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) (46-48), treatment withdrawal (49;50) and others.  
 
In summary, combined NOD2/ATG16L1 variant genotypes identify a patient subgroup 
with an increased risk of bactDNA translocation. This fact may, in turn, exacerbate 
the inflammatory response and is directly associated with disease activity and the 
risk of relapse in the short-term. This persistent inflammatory environment would 
favour the requirement for therapy intensification in mutated patients on treatment 
with biologics, who would probably be candidates for a different therapeutic strategy.   
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Figure legends. 
 
Figure 1. (A) Distribution of NOD2/ATG16L1-combined genotypes in CD patients 
stratified by CDAI. (B) Percentage of bactDNA presence in each studied genotype 
distributed by CDAI; *p<0.01 compared with the wtNOD2/wtATG16L1 genotype 
group. CDAI: Crohn’s disease activity index; bactDNA: bacterial DNA; wt: wild-type; 
var: variant. 
 
Figure 2. Phagocytic (A) and bactericidal (B) activities in neutrophils of patients with 
NOD2 / ATG16L1 combined genotypes (n=12/each group) without bactDNA 
translocation into blood; * p<0.01 compared with wtNOD2 groups. 
 
Figure 3. (A) Percentage of patients on intensified anti-TNF-α therapy stratified 
according to NOD2/ATG16L1-combined genotypes. (B) Percentage of patients on 
intensified anti-TNF-α therapy according to the presence of bactDNA. (C) Free anti-
TNF-α levels in serum of patients receiving therapy with biologics, either alone or 
combined with immunosuppressive treatment, stratified according to each genotype 
studied as well as to the presence of bactDNA; *p<0.01 compared with wtNOD2 
groups. (D) Free anti-TNF-α levels in serum of patients on monotherapy with 
biologics, stratified according to each genotype studied and to the presence of 
bactDNA; *p<0.01 compared with wtNOD2 groups. 
 
Figure 4. (A) TNF-α levels in the supernatants of neutrophils from patients with 
different NOD2/ATG16L1 genotypes exposed to E. coli-DNA; $p<0.01 compared with 
baseline and unstimulated conditions; *p<0.01 compared with wtNOD2 groups. (B) 
Apoptotic activity of 24-hour cultured neutrophils from patients of each genotype 
subgroup. (C) Free anti-TNF-α levels in the supernatants of neutrophils from patients 
with studied NOD2/ATG16L1 genotypes exposed to E. coli-DNA and treated with 
Infliximab; *p<0.01 compared with wtNOD2 groups. (D) Apoptotic activity of 72-
hour cultured neutrophils from patients of each genotype subgroup. 
 
 
Table 1. Patient characteristics. 
 
Age (years)
Weight (kg) 70,12 ± 15,76 68,88 ± 20,78
Genre (male/female)
Smoking habit n (%)
Disease duration (months)
Resection n (%)
Montreal A (age of onset) n (%)
A1 (<=16)
A2 (17-40)
A3 (>40)
Montreal L (location) n (%)
L1 (ileal)
L2 (colonic)
L3 (ileocolonic)
L4 (upper isolated)
Montreal B (behaviour) n(%)
B1 (non-stricturing, non-penetrating)
B1p (non-stricturing, non-penetrating, penetrating 
perianal disease)
B2 (stricturing)
B2p (stricturing, perianal disease associated)
B3 (penetrating)
B3p (penetrating, penetrating perianal disease)
Therapy n (%)
Mesalazine
Steroids
Azathioprine
Infliximab
Adalimumab
Metotrexate
Mesalazine and Steroids
Mesalazine and Azathioprine
Azathioprine and Steroids
Infliximab and Azathioprine
Adalimumab and Azathioprine
Infliximab and Metotrexate
Infliximab and Steroids
Adalimumab and Steroids
Infliximab and Azathioprine and Steroids
No treatment
ESR (mm) 19.4 ± 16.3 40.5 ± 27.4 *
CRP (mg/dL) 0,53 ± 1,04 3,43 ± 4,99 *
Hemoglobin (g/dL) 13,93 ± 3,02 12,49 ± 1,66 *
Albumin (mg/dL) 4073,05 ± 453,02 3588,2 ± 573,47 *
Total WBCs (mm3) 6907,7 ± 2757,24 7725,02 ± 2642,26
Temperature (ºC) 36,09 ± 0,26 36,54 ± 0,58 *
Pulse rate (bpm) 70,17 ± 5,43 72 ± 7,47
-
1 (2,4%)
All values shown as mean ± standard deviation or percentage. ESR: erythrocyte sedimentation rate; CRP: C-
reactive protein; * p<0.05 when compared with CDA index<150
5 (3,6%) -
2 (1,4%) -
-
2 (1,4%)
1 (2,3%)
49 (36,0%) 4 (9,3%) *
2 (1,4%) 10 (23,2)% *
2 (4,6%)
5 (11,6%)7 (5,1%)
3 (2,2%)
7 (5,1%)
5 (11,6%)
8 (5,8%) 4 (9,3%)
1 (0,7%)
3 (2,2%)
2 (4,6%)
-
- 2 (4,6%)
24 (17,6%) 5 (13,6)%
4 (2,9%) 4 (9,3)%
2 (4,6%)
22 (16,3%) 13 (30,2%)
35 (25,7%) 5 (11,6%) *
-
11 (8%)
7 (5,1%)
10 (23,3%)
68 (50%) 19 (44,2%)
3 (2,2%)
32 (23,5%)
70 (51,4%) 23 (53,4%)
65/71
107 (78,6%) 30 (69,7%)
48 (35%) 14 (32%)
18/24
112,52 ± 91,66 106,54 ± 98,19
6 (4,4%) 3 (7%)
CDA Index
<150 (n=136) >150 (n=43)
40 ± 14 42 ± 15
2 (4,6%)
-
12 (8,8%) 
13 (30%)36 (26%)
5 (11,6%)
31 (22,8%) 12 (28%)
3 (7%)
23 (17%)
 
 
Table 2. Distribution of genotypes and allelic frequencies in CD patients and controls. 
 
 
Gentotype [n (%) patients / controls]
Homozygous wild-type Heterozygous Homozygous variant Variant allele frequency (%)
NOD2 SNP8 (R702W) 136 (76%) / 24 (96%) 43 (24%) / 1 (4%) 0 / 0 12.0 / 2.0
NOD2 SNP12 (G908R) 152 (85%) / 24 (96%) 26 (14.5%) / 1 (4%) 1 (0.5%) / 0 7.8 / 2.0
NOD2 SNP13 (L1007finsC) 164 (92%) / 24 (96%) 15 (8.4%) / 1 (4%) 0 / 0 4.7 / 2.0
ATG16L1 (T300A) 73 (41%) / 22 (88%) 84 (47%) / 5 (20%) 22 (12.3%) / 0 35.8 / 10.0  
 
Table 3. Multivariate analyses on disease activity (A), bacterial DNA (B) and relapse 
at 6 months (C) including variables with a p value <0.1 on univariate analysis.  
A) 
Dependent variable: Disease activity (CDAI < 150/CDAI > 150) 
Multivariate analysis 
Variable P OR 95%CI 
Presence of bacterial DNA fragments (yes/no) 0.008 7.422 1.690 – 32.596 
Steroids treatment (yes/no) 0.001 27.303 4,233 – 176,116 
Infliximab treatment (yes/no) 0.001 16.649 3.213 – 86.288 
C-reactive protein (mg/dL) 0.001 3.833 1.679 – 8.752 
 
B) 
Dependent variable: bacterial DNA 
Multivariate analysis 
Variable P OR 95%CI 
Disease activity (CDAI > 150/CDAI < 150) 0.001 5.084 1.972 – 13.106 
Genotype 
         wtNOD2/wtATG16L1 
         varNOD2/wtATG16L1 
         wtNOD2/varATG16L1 
         varNOD2/varATG16L1 
 
0.000 
0.020 
0.0401 
0.000 
 
  
5.117 
2.221 
12.728 
 
 
1.287 – 20.346 
1.394 – 5.118 
3.738 – 43.344 
 
C) 
Dependent variable: Relapse at 6 months (yes/no) 
Multivariate analysis 
Variable P OR 95%CI 
Presence of bacterial DNA fragments (yes/no) 0.003 5.132 1.764 – 14.926 
 
 
Table 4. Serum cytokine levels in patients with different NOD2/ATG16L1-combined 
genotypes according to the presence of bactDNA. 
 
wtNOD2 / wtATG16L1 (n=43) 28,08 ± 6,89 30,21 ± 4,06 54,19 ± 7,70
BactDNA - varNOD2 / wtATG16L1 (n=18) 28,71 ± 4,91 31,81 ± 4,37 52,31 ± 6,45
(n=128) wtNOD2 / varATG16L1 (n=48) 30,09 ± 4,50 34,78 ± 7,64 52,64 ± 5,71
varNOD2 / varATG16L1 (n=19) 30,12 ± 3,48 32,04 ± 5,70 50,72 ± 5,20
wtNOD2 / wtATG16L1 (n=5) 49,57 ± 6,92 * 59,32 ± 6,1 * 91,16 ± 11,8 *
BactDNA + varNOD2 / wtATG16L1 (n=8) 75,67 ± 7,80 * † 82,86 ± 7,48 * † 124,01 ± 15,5 * †
(n=51) wtNOD2 / varATG16L1 (n=9) 50,70 ± 8,73 * 61,43 ± 6,6 * 98,73 ± 12,43 *
varNOD2 / varATG16L1 (n=29) 79,50 ± 8,93 * † 85,60 ± 8,27 * † 138,49 ± 17,5 * †
* p<0.01 compared with same genotype in bactDNA negative patients;
†  p<0.01 compared with the wtNOD2 genotypes in bactDNA positive patients.
TFN-alpha (pg/mL) IFN-gamma (pg/mL) IL-12 (pg/mL)
 
 
 
 
 
